Table 3 Prognostic significance of circulating DNA in breast cancer patients (based on: 22 , only trials with at least 100 patients were included).
| Trial | Number of patients | Setting | Technique: | Prognostic significance: OS |
|---|---|---|---|---|
|
1
Serum
2 Plasma Acronyms: dPCR – digital PCR; HR – hazard ratio; OSMSP – one-step methylation-specific PCR; PCR-SSCP – PCR-single-strand conformation polymorphism; RFS – relapse-free survival | ||||
| Fujita et al. 23 | 336 | Stage I – II |
OSMSP
1
Met-DNA (±)/Total cfDNA (high/low) |
OS:
Yes (HR for Met-DNA 3.17; for total cfDNA 4.03) DFS/RFS: Met-DNA: No (HR 2.3) Total cfDNA: Yes (2.70) |
| Fernandaz-Garcia et al. 24 | 194 | Stage IV | TaqMan, RT-PCR Total cfDNA (high/low) |
OS:
yes (HR 2.296) |
| BRE12–158 25 | 151 | Stage I – III triple-negative, non-pCR |
FoundationOne Liquid
2
ctDNA (±) |
OS:
yes (HR 2.7) DDFS: yes (HR 3.1) |
| Garcia et al. 26 | 142 | Stage I – III |
PCR-SSCP
2
ctDNA (±) |
OS:
no (HR 1.60) DFS/RFS: yes (HR 2.70) |
| Fujita et al. 27 | 120 | Stage II – III post-therapy |
OSMSP
1
Met-DNA (±)/Total cfDNA (high/low) |
OS:
yes (HR for Met-DNA 4.91; for total cfDNA 4.11) DFS/RFS: yes (HR for Met-DNA 4.23; for total cfDNA 1.93) |
| Shaw et al. 28 | 112 | Stage IV |
ddPCR
2
Total cfDNA |
OS:
yes (HR 2.20) |
| Shaw et al. 29 | 110 | Stage I – III |
dPCR
1
mut. PIK3CA (±) |
OS:
no (HR 3.92) DFS/RFS: yes (HR 4.78) |